Press Release

ZEISS opens modern research and production facility

ZEISS Medical Technology strengthens its international network by expanding its site in Chesterfield (Missouri, USA)

30 September 2024

Jena, Germany / Chesterfield, USA | September 30, 2024 | Carl Zeiss Meditec AG

ZEISS Medical Technology invests continuously in its international locations and opens a new state-of-the-art research and production facility in Chesterfield (Missouri, USA) on October 1, 2024. ZEISS expanded the range of surgical instruments it offers when it acquired the two Chesterfield-based companies Kogent Surgical LLC and Katalyst Surgical LCC in 2022. Additional building space was acquired for these product areas and converted into modern production and office space.

"With the expansion, we offer our local team a highly attractive working environment. At the same time, we are increasing our capacities in response to the growing success of our business," emphasizes Magnus Reibenspiess, Head of the Microsurgery strategic business unit.

Signage of ZEISS facility in Chesterfied (Missouri, USA)

Signage of ZEISS facility in Chesterfied (Missouri, USA)

Continuous growth

The ZEISS corporate strategy includes expanding the global production network, aimed in part at strengthening the companyā€™s operational excellence. More than 160 people work at the Chesterfield site, and the new building will expand the overall area to 64,500 square feet. It includes modern research and production facilities and a 2,300 square feet ISO 7-certified clean room.

"The new space will help us to optimize the production processes in Chesterfield by improving material flows ā€“ thus increasing our productivity while maintaining our high-quality levels," says Hartmut A. Koenig, Head of ZEISS Competence Center Chesterfield. "We are confident that the new building complex will help us to strengthen our position in the surgical instrument market."

A positive signal for the region

Home to more than 2,000 companies and providing jobs for over 42,000 employees, Chesterfield is a powerful economic hub in the westernmost part of St. Louis County, Missouri (USA).

ā€œSt. Louis County continues to demonstrate that this is the place for innovative companies to expand their global reach,ā€ said St. Louis County Executive Dr. Sam Page. ā€œWe welcome ZEISS to Chesterfield and appreciate the investment they are making in our region.ā€

Innovations for surgical procedures

ZEISS has been driving progress in medical technology for more than 100 years. The company develops and produces ophthalmological and microsurgical instruments at its site in Chesterfield. Learn more about electrosurgical instruments from ZEISS at https://www.zeiss.com/meditec/en/products/microsurgical-instruments.html.

Press & Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
investors.med@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of ā‚¬2,089.3m in fiscal year 2022/23 (to 30 September).

The Groupā€™s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AGā€™s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the worldā€™s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

Ā 

Press Photos

  • Signage of ZEISS facility in Chesterfied (Missouri, USA)

    File size: 2 MB

Share this page